(PQ9)A redox-mediated mechanism of chemotherapy-induced cognitive impairment
(PQ9)化疗引起的认知障碍的氧化还原介导机制
基本信息
- 批准号:9363914
- 负责人:
- 金额:$ 45.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-09-15 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:4 hydroxynonenalAddressAlpha CellAnimal ModelAntibodiesAntineoplastic AgentsAntioxidantsApoptoticBCL2 geneBiochemicalBlood - brain barrier anatomyBlood CirculationBrainBrain InjuriesCancer PatientCancer SurvivorCellsCholineClinicalClinical TrialsCognitionConfusionCytotoxic ChemotherapyDevelopmentDoxorubicinDrug TargetingDrug usageEtiologyFamilyFunctional disorderFutureGenerationsGoalsImmuneImpaired cognitionImpairmentIn VitroInflammatoryInjuryIntrathecal ChemotherapyKnockout MiceLinkLymphomaMagnetic Resonance SpectroscopyMediatingMediator of activation proteinMemoryMitochondriaModelingMolecularMusNeuraxisNeuronal InjuryNitratesOxidation-ReductionOxidative StressPathologyPatientsPeripheralPermeabilityPharmaceutical PreparationsPlasmaPreventionProductionProteinsProteomicsPublishingQuality of lifeRadiationReactionReactive Oxygen SpeciesRecommendationResearchRespirationRiskRoleSOD2 geneSymptomsSyndromeSystemic TherapyTNF geneTechnologyTestingTherapeutic EffectTherapeutic UsesTissuesToxic effectToxicity due to chemotherapyTreatment EfficacyUnited StatesVisionantioxidant enzymecancer cellcancer therapychemobrainchemotherapycytokinecytotoxicdesignexecutive functionexperienceextracellular vesiclesimprovedin vivoinhibitor/antagonistinsightmacrophagemimeticsmitochondrial dysfunctionmultitaskneuron lossnitrationnovelpreventprototypespecific biomarkerstargeted treatmenttumor
项目摘要
Project Summary
This application addresses the Provocative Question 9: "What are the molecular and/or cellular mechanisms
that underlie the development of cancer therapy-induced severe adverse sequelae?" focusing on
Chemotherapy-induced cognitive impairments (CICI). CICI is now a recognized toxicity syndrome that includes
loss of executive function (confusion; memory issues), inability to multitask, and impaired intellectual
reasoning. While CICI caused by central nervous system (CNS)-directed therapies (such as radiation and
intrathecal chemotherapy) is readily understood, the mechanisms underlying a critical and shared toxicity of
chemotherapy that occurs after systemic cancer treatment with drugs that did not direct at the brain, are
unclear. The number of patients at risk for CICI from systemic therapy far exceeds the number of patients
exposed to CNS therapy, but little is known about the mechanisms mediating the effect of systemic therapy on
CICI, and there is no clear vision of how to prevent this condition. We have previously shown that generation
of reactive oxygen species (ROS) by cytotoxic chemotherapeutic drugs is an essential mediator of brain injury
even though the drug itself did not get into the brain. It is also imperative to note that anticancer medications,
designed specifically to target cancer cells with specialized features, such as the family of Bcl2 inhibitors, also
generate ROS. However, the effect of targeted therapy on CICI has never been addressed, and,
consequently, their mechanisms of action are entirely unknown. The goal of this proposal is to test the overall
hypothesis that therapy-induced ROS production in the target tissues leads to increased circulating TNFα
through extracellular vesicles (EVs)-mediated reactions, and this pro-inflammatory cytokine crosses the blood
brain barrier to elicit mitochondrial dysfunction and consequent neuronal injury leading to CICI. The following
specific aims are designed to test the ROS hypothesis, gain an understanding of the EVs-mediated
mechanisms, and test the proof-of-concept in an experimental cancer therapy setting using two prototype
chemotherapy agents (Doxorubicin and Venetoclax) that represent standard cytotoxic and experimental
targeted drugs in a lymphoma model. Aim 1 will investigate the fundamental role of TNFα in therapy-induced
neuronal injury to gain insights into mechanisms of CICI in the brain and demonstrate efficacy of chemotherapy
in the presence of redox-active antioxidants. Aim 2 will determine the mechanistic links between circulating
extracellular vesicles and therapy-induced CICI. Aim 3 will define the cell(s) of origin of TNFα produced during
chemotherapy that leads to cognitive impairment. These aims will be accomplished in vitro and in vivo using
state-of-the-art technologies, including magnetic resonance spectroscopy, redox proteomics, unique animal
models, and novel mitochondria targeting anti-oxidant, MnP, to ameliorate CICI without reducing the efficacy of
the anti-cancer drugs. The results from this project will lay important groundwork for future clinical trials to
improve the quality of lives of cancer patients exposed to cytotoxic or targeted therapies.
项目摘要
这个应用程序解决了挑衅性问题9:“什么是分子和/或细胞机制
导致癌症治疗引起的严重不良后遗症的潜在原因“聚焦于
化疗引起的认知障碍(CICI)。CICI现在是一种公认的毒性综合征,包括
执行功能丧失(混乱;记忆问题),无法进行多任务处理,智力受损
推理虽然CICI由中枢神经系统(CNS)定向治疗(例如放射和化疗)引起,
鞘内化疗)是容易理解的,潜在的机制是一个关键的和共享的毒性,
在使用不直接针对大脑的药物进行系统性癌症治疗后发生的化疗,
不清楚全身治疗导致CICI风险的患者数量远远超过
暴露于中枢神经系统治疗,但很少有人知道的机制介导的作用,全身治疗
CICI,并且对于如何预防这种情况没有明确的愿景。我们之前已经证明了这一代人
细胞毒性化疗药物引起的活性氧(ROS)是脑损伤的重要介质
尽管药物本身并没有进入大脑。还必须注意的是,抗癌药物,
专门设计用于靶向具有特定特征的癌细胞,例如Bcl 2抑制剂家族,
产生ROS。然而,靶向治疗对CICI的影响从未得到解决,并且,
因此,其作用机制完全未知。本提案的目标是测试
假设治疗诱导的ROS在靶组织中产生导致循环TNFα增加
通过细胞外囊泡(EV)介导的反应,这种促炎细胞因子穿过血液
脑屏障引起线粒体功能障碍和随后的神经元损伤,导致CICI。以下
具体的目的是为了测试ROS假设,了解EV介导的
机制,并使用两个原型在实验性癌症治疗环境中测试概念验证
化疗药物(阿霉素和维奈托克),代表标准的细胞毒性和实验
淋巴瘤模型中的靶向药物。目的1探讨肿瘤坏死因子α(TNFα)在治疗诱导的肿瘤细胞凋亡中的作用。
神经元损伤,以深入了解脑中CICI的机制并证明化疗的疗效
在氧化还原活性抗氧化剂的存在下。目标2将确定循环与
细胞外囊泡和治疗诱导的CICI。目的3将定义在肿瘤生长过程中产生TNFα的细胞来源。
化疗会导致认知障碍这些目标将在体外和体内实现,
国家的最先进的技术,包括磁共振光谱,氧化还原蛋白质组学,独特的动物
模型,和新的线粒体靶向抗氧化剂,MNP,以改善CICI,而不降低疗效,
抗癌药物。该项目的结果将为未来的临床试验奠定重要基础,
改善暴露于细胞毒性或靶向治疗的癌症患者的生活质量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
SUBBARAO BONDADA其他文献
SUBBARAO BONDADA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('SUBBARAO BONDADA', 18)}}的其他基金
(PQ9)A redox-mediated mechanism of chemotherapy-induced cognitive impairment
(PQ9)化疗引起的认知障碍的氧化还原介导机制
- 批准号:
9982850 - 财政年份:2017
- 资助金额:
$ 45.51万 - 项目类别:
(PQ9)A redox-mediated mechanism of chemotherapy-induced cognitive impairment
(PQ9)化疗引起的认知障碍的氧化还原介导机制
- 批准号:
10216188 - 财政年份:2017
- 资助金额:
$ 45.51万 - 项目类别:
Role of Tcl1 and Par-4 in regulation of chronic lymphocytic leukemia
Tcl1和Par-4在慢性淋巴细胞白血病的调节中的作用
- 批准号:
8792347 - 财政年份:2013
- 资助金额:
$ 45.51万 - 项目类别:
Role of Tcl1 and Par-4 in regulation of chronic lymphocytic leukemia
Tcl1和Par-4在慢性淋巴细胞白血病的调节中的作用
- 批准号:
9205218 - 财政年份:2013
- 资助金额:
$ 45.51万 - 项目类别:
Role of Tcl1 and Par-4 in regulation of chronic lymphocytic leukemia
Tcl1和Par-4在慢性淋巴细胞白血病的调节中的作用
- 批准号:
8440656 - 财政年份:2013
- 资助金额:
$ 45.51万 - 项目类别:
Role of Tcl1 and Par-4 in regulation of chronic lymphocytic leukemia
Tcl1和Par-4在慢性淋巴细胞白血病的调节中的作用
- 批准号:
8616359 - 财政年份:2013
- 资助金额:
$ 45.51万 - 项目类别:
Role of Tcl1 and Par-4 in regulation of chronic lymphocytic leukemia
Tcl1和Par-4在慢性淋巴细胞白血病的调节中的作用
- 批准号:
8997402 - 财政年份:2013
- 资助金额:
$ 45.51万 - 项目类别:
Importance of CD5 for the function of regulatory T cells
CD5 对于调节性 T 细胞功能的重要性
- 批准号:
7640703 - 财政年份:2008
- 资助金额:
$ 45.51万 - 项目类别:
Importance of CD5 for the function of regulatory T cells
CD5 对于调节性 T 细胞功能的重要性
- 批准号:
7471782 - 财政年份:2008
- 资助金额:
$ 45.51万 - 项目类别:
Growth Regulation and Therapy of Leukemias and Lymphomas
白血病和淋巴瘤的生长调节和治疗
- 批准号:
7122013 - 财政年份:2003
- 资助金额:
$ 45.51万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 45.51万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 45.51万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 45.51万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 45.51万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 45.51万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 45.51万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 45.51万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 45.51万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 45.51万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 45.51万 - 项目类别:
Research Grant